1. Home
  2. PAHC vs DNTH Comparison

PAHC vs DNTH Comparison

Compare PAHC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phibro Animal Health Corporation

PAHC

Phibro Animal Health Corporation

HOLD

Current Price

$38.78

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$50.70

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAHC
DNTH
Founded
1946
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
PAHC
DNTH
Price
$38.78
$50.70
Analyst Decision
Hold
Strong Buy
Analyst Count
4
9
Target Price
$31.25
$68.88
AVG Volume (30 Days)
202.2K
770.6K
Earning Date
02-05-2026
03-10-2026
Dividend Yield
1.22%
N/A
EPS Growth
288.74
N/A
EPS
1.67
N/A
Revenue
$1,399,676,000.00
$3,078,000.00
Revenue This Year
$15.34
N/A
Revenue Next Year
$3.28
N/A
P/E Ratio
$23.66
N/A
Revenue Growth
33.72
N/A
52 Week Low
$16.16
$13.37
52 Week High
$46.42
$54.00

Technical Indicators

Market Signals
Indicator
PAHC
DNTH
Relative Strength Index (RSI) 44.18 66.34
Support Level $38.29 $50.00
Resistance Level $39.91 $52.02
Average True Range (ATR) 1.44 3.07
MACD -0.06 0.91
Stochastic Oscillator 16.60 81.15

Price Performance

Historical Comparison
PAHC
DNTH

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: